Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.71 |
| ▸ | AKT2 | P31751 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.53 |
| ▸ | SYK | P43405 | 4/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | FCER2 | P06734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728497 | 1.00 | KDR (0.71) | KDRFGFR1PDGFRBAKT2EGFR | |
| SCHEMBL2115487 | 0.88 | AKT2 (0.65) | KDRFGFR1PDGFRBAKT2EGFR | |
| SCHEMBL2115490 | 0.88 | AKT2 (0.65) | KDRFGFR1PDGFRBAKT2EGFR | |
| SCHEMBL6514860 | 0.84 | AKT2 (0.58) | KDRFGFR1PDGFRBAKT2EGFR | |
| SCHEMBL4407240 | 0.83 | KDR (1.00) | KDRFGFR1PDGFRBAKT2EGFR | |
| SCHEMBL4407243 | 0.83 | KDR (1.00) | KDRFGFR1PDGFRBAKT2EGFR | |
| SCHEMBL22917527 | 0.83 | AKT2 (0.69) | KDRFGFR1PDGFRBAKT2CDK2 | |
| SCHEMBL29911476 | 0.83 | AKT2 (0.69) | KDRFGFR1PDGFRBAKT2CDK2 | |
| SCHEMBL15202702 | 0.82 | AKT2 (0.66) | KDRFGFR1PDGFRBAKT2CDK2 | |
| SCHEMBL6514642 | 0.81 | AKT2 (0.54) | KDRFGFR1PDGFRBAKT2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | KDR 2521/4885FGFR1 833/4885PDGFRB 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.